International Health News

Hydrazine sulfate in cancer therapy

TORONTO, CANADA. Cachexia (general weakness and loss of weight and appetite) is a serious complication in many forms of cancer. There is now evidence that hydrazine sulfate given orally or by injection may reduce the severity of cachexia and improve the quality of life in cancer patients. There are also some still controversial indications that hydrazine sulfate may inhibit tumor growth and improve survival. The use of hydrazine sulfate in cancer therapy was first proposed by Dr. Joseph Gold, an oncologist at the Syracuse Cancer Research Institute. Since Dr. Gold's discovery extensive research on hydrazine sulfate has been carried out in Russia and the United States. The Russian studies report significant improvements in well-being and survival while the results of the American studies are more ambiguous. Hydrazine sulfate is legally available to physicians in both Canada and the United States. It is usually given orally (60 mg three times daily) over a period of 30-45 days followed by a rest period of two to six weeks. There are no serious side effects but Dr. Gold cautions that alcohol, barbiturates, and tranquillizers (particularly benzodiazepines) interfere with the effectiveness of hydrazine sulfate. Because hydrazine sulfate is a monoamine oxidase inhibitor it is also advisable to avoid foods rich in tyramine during therapy. This therapy is compatible with and may enhance conventional therapies, especially chemotherapy.
Kaegi, Elizabeth. Unconventional therapies for cancer: 4. Hydrazine sulfate. Canadian Medical Association Journal, Vol. 158, May 19, 1998, pp. 1327-30

category search
Keyword Search

My favourite Supplements

copyright notice